Ustekinumab is a human monoclonal antibody that inhibits the p40 subunit of interleukin 12 and 23, thus inhibiting the differentiation of T cells into Th1 and Th17 cells and reducing inflammatory cytokines. It is approved for treatment of moderate to severe plaque psoriasis. Rituximab is a chimeric monoclonal antibody against CD20 that causes depletion of mature B cells. It is used off-label for various autoimmune blistering disorders. Belimumab inhibits BLyS, which plays a key role in B cell development, and is approved for treatment of systemic lupus erythematosus.
This presentation includes -classification, biological in psoriasis,TNF alpha inbitors, T cell inhibitos, IL-12/23 inhibitors (indications,containdications,guidelines, adverse effects)
This PPT covers drug therapy for tuberculosis. It includes classification of antitubercular drugs, chemotherapy for tuberculosis, strategies for addressing resistance and pharmacotherapy of antitubercular drugs
Anti Tubercular Drugs - Mechanism of Action and Adverse effects Thomas Kurian
A brief outline of the mechanism of action and adverse effects of anti tubercular drugs
Only First line and second line drugs are dealt with.First line drugs may be useful for MBBS students and the rest is directed for postgraduate students.
Hope you find it useful.
This presentation includes -classification, biological in psoriasis,TNF alpha inbitors, T cell inhibitos, IL-12/23 inhibitors (indications,containdications,guidelines, adverse effects)
This PPT covers drug therapy for tuberculosis. It includes classification of antitubercular drugs, chemotherapy for tuberculosis, strategies for addressing resistance and pharmacotherapy of antitubercular drugs
Anti Tubercular Drugs - Mechanism of Action and Adverse effects Thomas Kurian
A brief outline of the mechanism of action and adverse effects of anti tubercular drugs
Only First line and second line drugs are dealt with.First line drugs may be useful for MBBS students and the rest is directed for postgraduate students.
Hope you find it useful.
Immunosuppressants are drugs which inhibit cellular/humoral or both types of immune responses and have their major use in organ transplantation and autoimmune diseases.
Immunosuppressants are drugs which inhibit cellular/humoral or both types of immune responses and have their major use in organ transplantation and autoimmune diseases.
This PPT encompasses the recent biologics overview & their uses in various rheumatological diseases according to recent guidelines. Special focus has been given to RA, SpA & SLE
Here is a very comprehensive lecture about ITP, its types , signs and symptoms and management. This lecture presentation was delivered by Dr Nida TMO in MBW HMC Peshawar Pakistan.
Vaccination in immunosuppressed adults - Slideset by professor Katie FlanaganWAidid
Immune compromised persons are generally at increased risk of morbidity and mortality from many vaccine preventable diseases, but since many vaccines, especially the live ones, are contraindicated in many immunocompromising situations, the degree of patients' impairment should be assessed each time in order to determine the best vaccination strategy...
To learn more, please visit www.waidid.org.
PRESENTATION 4- Basics of Laser in Dermatolgy
It includes -
Laser spectrum
Definition Laser
Classification of Lasers
Laser Theories
Laser terminology
Laser Hazards
Palestine last event orientationfvgnh .pptxRaedMohamed3
An EFL lesson about the current events in Palestine. It is intended to be for intermediate students who wish to increase their listening skills through a short lesson in power point.
Acetabularia Information For Class 9 .docxvaibhavrinwa19
Acetabularia acetabulum is a single-celled green alga that in its vegetative state is morphologically differentiated into a basal rhizoid and an axially elongated stalk, which bears whorls of branching hairs. The single diploid nucleus resides in the rhizoid.
Operation “Blue Star” is the only event in the history of Independent India where the state went into war with its own people. Even after about 40 years it is not clear if it was culmination of states anger over people of the region, a political game of power or start of dictatorial chapter in the democratic setup.
The people of Punjab felt alienated from main stream due to denial of their just demands during a long democratic struggle since independence. As it happen all over the word, it led to militant struggle with great loss of lives of military, police and civilian personnel. Killing of Indira Gandhi and massacre of innocent Sikhs in Delhi and other India cities was also associated with this movement.
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Francesca Gottschalk - How can education support child empowerment.pptxEduSkills OECD
Francesca Gottschalk from the OECD’s Centre for Educational Research and Innovation presents at the Ask an Expert Webinar: How can education support child empowerment?
Biological screening of herbal drugs: Introduction and Need for
Phyto-Pharmacological Screening, New Strategies for evaluating
Natural Products, In vitro evaluation techniques for Antioxidants, Antimicrobial and Anticancer drugs. In vivo evaluation techniques
for Anti-inflammatory, Antiulcer, Anticancer, Wound healing, Antidiabetic, Hepatoprotective, Cardio protective, Diuretics and
Antifertility, Toxicity studies as per OECD guidelines
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdfTechSoup
In this webinar you will learn how your organization can access TechSoup's wide variety of product discount and donation programs. From hardware to software, we'll give you a tour of the tools available to help your nonprofit with productivity, collaboration, financial management, donor tracking, security, and more.
Synthetic Fiber Construction in lab .pptxPavel ( NSTU)
Synthetic fiber production is a fascinating and complex field that blends chemistry, engineering, and environmental science. By understanding these aspects, students can gain a comprehensive view of synthetic fiber production, its impact on society and the environment, and the potential for future innovations. Synthetic fibers play a crucial role in modern society, impacting various aspects of daily life, industry, and the environment. ynthetic fibers are integral to modern life, offering a range of benefits from cost-effectiveness and versatility to innovative applications and performance characteristics. While they pose environmental challenges, ongoing research and development aim to create more sustainable and eco-friendly alternatives. Understanding the importance of synthetic fibers helps in appreciating their role in the economy, industry, and daily life, while also emphasizing the need for sustainable practices and innovation.
Read| The latest issue of The Challenger is here! We are thrilled to announce that our school paper has qualified for the NATIONAL SCHOOLS PRESS CONFERENCE (NSPC) 2024. Thank you for your unwavering support and trust. Dive into the stories that made us stand out!
The Roman Empire A Historical Colossus.pdfkaushalkr1407
The Roman Empire, a vast and enduring power, stands as one of history's most remarkable civilizations, leaving an indelible imprint on the world. It emerged from the Roman Republic, transitioning into an imperial powerhouse under the leadership of Augustus Caesar in 27 BCE. This transformation marked the beginning of an era defined by unprecedented territorial expansion, architectural marvels, and profound cultural influence.
The empire's roots lie in the city of Rome, founded, according to legend, by Romulus in 753 BCE. Over centuries, Rome evolved from a small settlement to a formidable republic, characterized by a complex political system with elected officials and checks on power. However, internal strife, class conflicts, and military ambitions paved the way for the end of the Republic. Julius Caesar’s dictatorship and subsequent assassination in 44 BCE created a power vacuum, leading to a civil war. Octavian, later Augustus, emerged victorious, heralding the Roman Empire’s birth.
Under Augustus, the empire experienced the Pax Romana, a 200-year period of relative peace and stability. Augustus reformed the military, established efficient administrative systems, and initiated grand construction projects. The empire's borders expanded, encompassing territories from Britain to Egypt and from Spain to the Euphrates. Roman legions, renowned for their discipline and engineering prowess, secured and maintained these vast territories, building roads, fortifications, and cities that facilitated control and integration.
The Roman Empire’s society was hierarchical, with a rigid class system. At the top were the patricians, wealthy elites who held significant political power. Below them were the plebeians, free citizens with limited political influence, and the vast numbers of slaves who formed the backbone of the economy. The family unit was central, governed by the paterfamilias, the male head who held absolute authority.
Culturally, the Romans were eclectic, absorbing and adapting elements from the civilizations they encountered, particularly the Greeks. Roman art, literature, and philosophy reflected this synthesis, creating a rich cultural tapestry. Latin, the Roman language, became the lingua franca of the Western world, influencing numerous modern languages.
Roman architecture and engineering achievements were monumental. They perfected the arch, vault, and dome, constructing enduring structures like the Colosseum, Pantheon, and aqueducts. These engineering marvels not only showcased Roman ingenuity but also served practical purposes, from public entertainment to water supply.
3. INTERLEUKIN 12/23 INHIBITORS
(Ustekinumab & Briakinumab)
• Interleukin 12 & 23 are secreted by APC’s and have
been identified as key ILs in development of psoriasis
• IL 12 & 23 causes diffrentiation of naïve T cells into Th1
and Th17 cells respectively
• This Th1 & Th17 T cells secrete various cytokines like IL
2, 6, 17, 21, 22, TNF alpha, IFN which are responsible
for inflammatory changes, keratinocyte
hyperproliferation and development of psoriatic
plaques
4. USTEKINUMAB
prefix-Uste, target-kin, origin-u
suffix-mab
• It is a newly developed, fully human monoclonal
IgG1 antibody directed against the comman p40
subunit of IL 12 & 23, thus inhibiting activity of
both interleukins on Tcell diffrentiation and
cytokine production
• Approved by US FDA in september 2009 for use
in moderate to severe plaque psoriasis
• As Ustekinumab and Briakinumab both are fully
humanised antibodies they are devoid of
decrease in efficacy due to antichimeric antibody
formation as seen with infliximab
6. INDICATIONS
• US FDA approved – mod. to severe plaque
psoriasis
• Off label indications – sarcoidosis
multiple sclerosis
7. Mode of administration & Dosage
• Indicated for treatment of adults (18 yrs and
above) with mod. to severe plaque psoriasis with
or without psoriatic arthritis who are candidates
for phototherapy and systemic therapy
• <100kg : 45mg SC initially, repeat after 4 wks and
then give 45mg SC every 12 wks
• >100kg : 90mg SC initially, repeat after 4 wks and
then give 90mg SC every 12 wks
• Can be combined with methotrexate in patients
with psoriatic arthritis
8. EFFICACY
• A double blind, placebo controlled phase 2
study in 320 pts with moderate to severe
plaque psoriasis showed PASI 90 score in
23% (one 45 mg dose),
30%(one 90mg dose),
44%(four weekly 45mg doses) and
52% (four weekly 90mg doses)
compared to 2% who received placebo
9. Adverse effects
Relatively less frequent like injection site
erythema, fatigue, myalgia, backache, mild
Infections (upper respiratory tract
infections), urticaria, rash
Rare reports of severe infections, malignancy,
precipitation of pustular or erythrodermic
Psoriasis and reversible posterior
leucoencephalopathy syndrome
10. CONTRAINDICATIONS
• Hypersensitivity
• Active serious infections
• Past h/o serious bacterial, fungal or viral infections – can
cause reactivation
• Concomitant live vaccines – discontinue atleast 15 wks
before live vaccines and resume atleast 2 wks later
• To be used cautiously in patients who are genetically
deficient in IL12 & 23
11. AVAILABILTY
Trade name – Inj. Stelara 45mg solution for
injection, SC use
Cost – 1 vial - 5500$ (3,33,000 INR)for
single
13. RITUXIMAB (anti CD20)
prefix-Ri, target-tu, origin-xi, suffix-mab
• It is a chimeric monoclonal antibody directed
against CD20 & acts by causing depletion of
CD20 positive cells by complement and
antibody dependent cytotoxicity.
• CD20 is expressed on the surface of B-cells
from pre B-cells to memory B-cells but not on
stem cells, pro B-cells nor on plasma cells
• Thus, Rituximab causes depletion of mature
B-cells which would transform into antibody
14. FDA approved :
CD20 +ve non-Hodgkins B cell lymphoma
Resistant rheumatoid arthritis
Wegeners granulomatosis
Microscopic polyangitis
Off label :Bullous dermatosis like -
Refractory pemphigus vulgaris
Paraneoplastic pemphigus
Bullous pemphigoid
Epidermolysis bulosa acquisita
Mucous membrane pemphigoid
Urticarial vasculitis
Connective tissue ds – SLE, Dermatomyositis
Primary cutaneous B-cell lymphoma
Acute and chronic graft versus host disease
INDICATION
S
15. CONTRAINDICATIONS
• Absolute - Known hypersensitivity to murine
proteins or rituximab
• Relative – h/o hypotension, bronchospasm,
angioedema
Pregnancy cat C
1 yr of contraception is advisable after
completion of Rituximab therapy.
16. No specific dosing regimen has been approved for
dermatologic uses
Usually given at a standard dose of 375 mg/m2
BSA i.v at weekly intervals
Monitoring blood counts & antibody levels should
be done every 2-3 months
17. • Pre-Rituximab evaluation
• Complete haemogram
• Liver function tests
• Renal function tests
• Chest X ray, Mantoux test
• Screening for viral infection including- HBsAg,
anti-HBc, anti- HCV, HIV-1 and HIV-2
• ECG and echocardiography
18. Pre-medication and rituximab
administration
• Premedications:
hydrocortisone 100 mg iv + pheniramine
maleate 22.75 mg iv + PCM 500 mg PO 30
min prior to infusion
• First infusion is administered at a rate of
50mg/h IV, escalated every 30min by 50mg/h
to a maximum infusion rate of 400mg/h,
total infusion time: 5–6h.
• Subsequent infusions are initiated at
100mg/h, with a 30-min escalation of 50mg/h
to a maximum infusion rate of 400mg/h.
19. Rituxan is a sterile, clear, colourless, preservative-free liquid
concentrate for IV administration.
Rituxan is supplied at a concentration of 10 mg/mL in either
100 mg (10 mL) or 500 mg (50 mL) single-use vials
• Reditux 100 mg(Rs. 10,000), 500 mg(Rs. 40,000)
20. Protocols
• Lymphoma protocol:
375mg/sqm BSA wkly for 4 wks
• RA protocol:
1 gm every 15 days
• Combination therapy:
combined with IVIG, immunoadsorption,
dexamethasone pulse therapy
Rheumatoid arthritis protocol is increasingly
used
21. ADVERSE EFFECTS
• Most comman a/e are infusion related like fever
and rigors. Others being flu like symptoms,
nausea, vomitting, abdominal pain,
hypotension.
• Treatment related s/e occurred most frequently
at first infusion(65%) and less often during 2nd
(15%), 3rd(5%) and 4th (5%) infusions.
• Other a/e like serious infections, SJS, TEN, sinus
tachycardia, dysrythmias, myocardial ischemia,
progressive multifocal leucoencephalopathy are
22. MANAGEMENT OF ADVERSE
REACTIONS
• In immediate reactions – treatment should be
discontinued. If possible after waiting for 30
mins rituximab infusion can be continued at
slow rate(half the initial rate). cortisone and
antihistamines should be readministered
23. BLyS INHIBITOR
(BELIMUMAB)
• BLyS family of proteins and their receptors plays a
key role in the survival and development of B
lymphocyte into mature B cells that produce
antibodies
• An over expression of BLyS in patients with SLE has
been observed with potential correlation between
serum levels of BLyS and SLE disease activity
• Belimumab is a fully human monoclonal antibody
that binds BLyS ,inhibits BLyS stimulation of B cell
development and finally restores the potential for
24. INDICATION
• Cases of SLE resistant to treatment or
frequently relapsing even after treatment with
corticosteroids, antimalarials,
immunosupressives and non steroidal anti-
inflammatory drugs
25. AVAILABILITY AND DOSING
• Premedications – antihistamines and
corticosteroids for prophylaxis against infusion
and hypersensitivity reactions
• Available as 120mg/vial and 400mg/vial
• Reconstituted in 0.9%NS and infused IV over
1 hr
Dose – 10mg/kg iv every 2 wks for 3 doses
Maintenance – 10 mg/kg iv every 4 wks
Cost for 1 yr treatment – 28000$ (1700000
26. Adverse effects
• Infusion related reactions like nausea, pyrexia,
skin rash, diarrhea are comman
• Other less comman A/E are nasopharyngitis,
bronchitis, insomnia, serious infections, pain
in extremities, depression, migraine
• Anaphylaxis and serious infusion reactions are
rare
• Pregnancy cat C drug
27. BIOLOGICALS FOR SLE
• Anti CD20 Ab – Rituximab, ocrelizumab
• Anti B lymphocyte stimulator – Belimumab,
Atacicept
• Anti CD22 Ab – Epratuzumab
• Anti CD11a Ab – Efalizumab
• Anti TNF alpha Ab – Infliximab, Etanercept,
Adalimumab, Certolizumab, Golimumab
• Anti IFN alpha Ab – sifalimumab, rontalizumab
• Anti IL1 Ab – Anakinra
• Anti IL6 Ab - Tocilizumab
• CD28-B7 interaction blocker – Abatacept
• Tolerogens – Abetimus, Edratide
28. DENILEUKIN DIFTITOX (
ONTAK )
It is an antineoplastic agent
consisting of a fragment of diphtheria toxin,
(which is involved in translocation and adenosine
diphosphate ribosyltransferase activity) , fused to
IL-2
29. • MOA – malignant cells of some leukemias and
lymphomas express IL2 receptors
-DENILEUKIN DIFTITOX binds to this IL-2
receptors and introduce diptheria toxin into
the cells, thus causing apoptosis of this
malignant cells
-inhibition of protein synthesis and cell
death
30. FDA approved –
Persistent or recurrent cutaneous T-cell
lymphoma (stage 3 and 4)
Administered -18 mcg/kg/day by iv infusion
over 30-60 minutes for 5 consecutive days every
21 days for 8 cycles
INDICATIONS
31. Anti IgE: Omalizumab
• It’s a recombinant, humanized, monoclonal
antibody against immunoglobulin IgE,
representing a unique approach for the
treatment of allergic diseases
• Prevents IgE from binding to its high affinity
mast cell receptor prevents mast cell
degranulation
33. • Omalizumab is approved for the treatment of
moderate to severe persistent asthama in
adults and adolescents older than 12 years of
age who have positive skin test to a perrenial
antigen
• It can be used in treatment of chronic
idiopathic urticaria and atopic dermatitis who
remain symptomatic despite of H1
antihistamine treatment
INDICATIONS
34. AVAILABILITY AND DOSAGE
• Doses: 150-375 mg SC at 2-4 wkly interval
• Available as Xolair (novartis), 150 mg/1.2ml inj
• Cost – 541$ (32,460 INR) for 150mg inj
35. First-line:
Second-generation H1-antihistamines
If symptoms persist after 2 weeks
Second-line:
Increase dosage of second generation
H1-antihistamines up to four-fold
If symptoms persist after further 1–4 weeks
Third-line:
Add omalizumab, cyclosporine A or leukotriene
antagonist
Short course (maximum 10 days) systemic corticosteroids may be used
at all times if exacerbations demand it
36. Second generation H1 Antihistamine (sgAH)
Increase sgAH (up to 4x)
Add Omalizumab, Cyclosporine, leukotriene
Antagonist
Short course of systemic corticosteroid may be tried for
exacerbations
If symptoms persist after 2 weeks
If symptoms persist after 1-4 weeks
Add Methotrexate, Dapsone, Autoserum therapy ,
H2 antihistamines
Indian Guidelines